Emerald Health Pharmaceuticals to Present at the 8th Annual LD Micro Invitational

SAN DIEGO, CA / ACCESSWIRE / May 31, 2018 / Emerald Health Pharmaceuticals Inc. (EHP), which is developing medicines based on cannabinoid science, will be featured as a presenting company at the upcoming LD Micro Invitational to be held on June 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Jill Broadfoot, Chief Financial Officer of EHP, will provide a corporate overview on Monday, June 4, 2018 at 2:00 PM PT/ 5:00 PM ET and will be available to meet with investors. If you would like to attend the Company’s presentation or schedule a meeting, please click on the following link: https://www.ldmicro.com/events.

This conference will feature 230 companies in the small-cap / micro-cap space, and will be attended by over 1,000 individuals.

About Emerald Health Pharmaceuticals Inc.

Emerald Health Pharmaceuticals is developing product candidates derived from cannabinoids for the treatment of CNS, autoimmune, and other diseases. The company has two families of new chemical entities, based on cannabidiol, CBD, and cannabigerol, CBG, that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its first drug candidate, EHP-101, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, is focused on treating Huntington’s disease and Parkinson’s disease. The company is advancing preclinical development with the intent to launch a Phase 1 clinical study in 2018. For more information, visit www.emeraldpharma.life or contact: info@emeraldpharma.life.

Forward-Looking Statements

To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered “forward-looking statements,” as described in the Private Securities Litigation Reform Act of 1995, that reflect management’s current beliefs and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; and (iv) our ability to raise capital. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals’ investigational drug products have not been approved or cleared by the FDA.

CONTACT:

Investor Relations
Phone: (800) 268-0719

SOURCE: Emerald Health Pharmaceuticals Inc.

ReleaseID: 501424